Immunohistochemical expression of vimentin and secretory component antigens in endometrial hyperplasia and neoplasia

Vimentin is an intermediate filament protein normally expressed in mesenchymal cells, but evidence is accumulating in the literature which suggests that the aberrant expression of vimentin in epithelial cancer cells might be related to local invasiveness and metastatic potential. Previous studies strongly support the implication of vimentin in the metastatic progression of breast and cervical lesions. The secretory component is isolated from human colostrum and is of help in more precise grading of endometrial carcinoma. In this study we examined vimentin and secretory component (SC) expression in adenomatous hyperplasia, atypical adenomatous hyperplasia and well-differentiated adenocarcinoma (cribriform pattern). The results showed decreased expression of vimentin and increased expression of the secretory component as the lesion progressed to malignancy.

Vimentin; Endometrial hyperplasia; Endometrial neoplasia

[1] OsbornM .,D ebus E、Weber K.: "Monoclonal antibodies specific for vimentin". Eu,: J. Cell. Biol., 1984, 34, 137.

[2] Franke W. W.. Schmid E.. Winter S., Osborn M.,W eber K.: "Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates". Exp. Cell. Res.,1979, 123, 25.

[3] Virtanen I., Lehto V. P.. Lehtonen E. et al.: "Expression of intermediate filaments in cultured cells". J. Cell. Biol., 1981, 50, 45.

[4] Sommers C., Walker-Jones D., Heckford S. E. et al.: "Yimentm rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells". Cancer Res., 1989, 49, 4258.

[5] Sommers S. L., Byers S. W.,T hompson E.W.,T orri J., Gelmann E. P.: "Differentiation state and invasiveness of human breast cancer cell lines". Breast Cancer Res. Treat., 1994, 31, 325.

[6] Giles C.. Piette J., Peter W., Fusenig N. E., Foidart J. M.: "Differentiation ability and oncogenic potential of HPV-33 or HPV-33+ras-transfected keratinocytes". Int. J. Cancer, 1994, 58, 847.

[7] Giles C., Polette M 、Piette J., Birembaut P.. Foidart J. M.: "Epithelial-to-mesenchymal transition in HPV-33-transfected cervical keratinocytes is associated with increased invasiveness and expression of gelatinase A". Int. J. Cancer. 1994, 59, 661.

[8] Azumi N.. Battifora H.: "The distribution of vimentin and keratm in epithelial and nonepithelial neoplasms". Am. J. Clin. Pathol., 1987, 188, 286.

[9] Miettinen M., Lehto V. P.. Virtanen I.: "Expression of intermediate filaments in normal ovaries and ovarian epithelial, sex cord stromal, and germinal tumors". Int. J. Gynecol. Pathol., 1983, 2, 64.

[10] Miettinen M., Franssila K., Lehto V. P., Paasivuo R., Virtanen I : "Expression of intermediate filament pr.oteins in thyroid gland and in thyroid tumors". Lab. Invest.. 1984, 50, 262.

[11] McNutt M.A., Bolen J. W., Gown A. M., Hammar S. P.. Vogel A M.: "Co-expression of intermediate filaments in human epithelial neoplasms". Ultrastruct. Pathol., 1985, 9, 31.

[12] Gatter K. C., Dunnill M. S., Van Muijen G. N. P.. Mason D. Y.: "Human lung tumors may coexpress different classes of intermediate filaments". J. Clin. Pathol., I 986, 39., 950.

[13] Upton M. P.. Hirobashi S., Tome Y., Miyazawa N., Sucmasu K., Shimosato Y.: "Expression of vimentin in surgica11y resected adenocarcinomas and large cell carcinomas of lung". Am. J. Surg. Pathol., 1986, 10, 560.

[14] Benjamin E., Law S., Bobrow L. G.: "Intermediate filaments cytokeratin and vimentin in ovarian sex cord-stromal tumors with correlative studies in adult and foetal ovaries". J. Pathol., 1987, 152, 253.

[15] Buley I. D.,G atter K. C.,H eryet A..M ason D. Y.: "Expression of intermediate filament proteins in normal and diseased thyroid glands". J. Clin. Pathol., 1987, 40, 136.

[16] Dogliono C.. Dell'Orto P..C oggi G.,I uzzolino P.. Bontempini L.: "Choroid plexus tumors. An immunocytochemical study with particular reference to the coexpression of intermediate filament proteins". Am. J. Pathol., 1987, 127, 519.

[17] lkegawa S.,S aida T.,T akizawa Y. et al.: "Vimentin-posillve squamous cell carcinoma arising in a burn scar". Arch. Dermatol., 1989, 125. 1672.

[18] Raymond W. A., Leong A. S. Y.: "Vimentin - a new prognostic parameter in breast carcinoma?". J. Pathol.. 1989, 158,107.

[19] Domagala W., Lasota J., Bartowiak J.. Weber K., sborn M.: "Vimentin is preferentially expressed in human breast carcinoma with low oestrogen receptor and high Ki-67 growth fraction". Am J. Pathol., 1990, 136, 219.

[20] Domagala W., Leszek W., Lasota J.. Weber K., Osborn M.: "Vimentin is preferentially expressed in high grade ductal and medullary, but not in lobular breast carcinoma". Am. J. Pathol., 1990, 137,1059.

[21] Gould V. E., Kouloulis G. K., Jansson D. S., Nagle R. B., Franke w.w., Moll R.: "Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast". Am. J. Pathol., 1990, 137, 1143.

[22] Raymond W. A., Leong A. S. Y.: "Coexpression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium". J. Pathol., 1989, 157, 299.

[23] Wada T., Yasutomi M., Hashmura K.. Kunikata M.. Tanaka T., Mori M.: "Yimentin expression in benign and malignant lesions in the human mammary gland". Anticancer Res., 1992, 122, 1973.

[24] Heatley M., Whiteside C., Maxwell P., Toner P.: "Virnentin in benign and malignant breast epithelium". J. Clin. Pathol., 1993, 46. 441.

[25] Domagala W., Striker G., Szadowska A., Dukowiez A.. Harezga B.: "Osborn M. P53 protein and vimentin in invasive ductal NOS breast carcinoma - relationship with survival and sites of metastases". Eur. J. Cancer, 1994, 30A, 1527.

[26] Bell C. D., Tiscler E. M., Laroye G. J.:'The relationship of cytoplasmic intermediate filaments and membrane antigens with hormone receptors, nuclear staining density, and mode of stromal invasion in human breast cancer". Breast Cancer Res. Treat., 1995, 33, 147.

[27] Gilles C., Polette M., Piette J., Delvigne A. C., Thompson E., Foidart J. M.. Birembaut P.: "Vimentin expression in cervical carcinomas: Association with invasive and migratory potential". J. Pathol., I 996, 180. 175.

[28] Nakopoulou L., Minaretzis D., Tsionou C., Mastrominas M.: "Value of immunohistochemical demonstration of several epithelial markers in hyperplastic and neoplastic endometrium". Gynecol. Oneal.. 1990, 37 (3), 346.

[29] Silverberg S. G., Kurman R. J.: "Tumors of the uterine corpus and gestational trophoblastic disease". Atlas of Tumor Pathology, AFIP Fascicle,3 rd Series,W ashington DC,1992.

[30] Scully R. E., Bonfiglio T. A.. Kurman R. J., Silverberg S. G., Wilkinson E. J.: "Uterine Corpus in Histological Typing of Female Genital Tract Tumors (WHO-Fascicle)''. Berlin, Heidelberg. New York: Springer, 1994.

[31] Bergeron C., Nogales F., Masseroli M., Abel er V., Duvillard P., Muller-Holzner E. et al.: "A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working (..lassification for biopsy and cunrrtage specimens". Am. J. Surg. Pathol., 1999, 23, 1102.

[32] Jacques S. M., Qureshi F., Munkarah A., Lawrence W. D.: "Interinstitutional surgical pathology review in gyne(..ologic oncology I. Cancer in endometrial curettings and biopsies". Int. J. Gynecol. Pathol.. 1998,17, 36.

[33] Kendall B. S.,R onnett B. M., Isacson C.,C ho K. R.,H edrick L., Diener-West M., Kurman R. J.: "Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma". Am. J. Surg. Pathol., 1998, 22, 1012.

[34] Mutter G. L. and The Endometrial Collaborative Group: "Endometrial intraepithelial neoplasia (ElN): will it bring order to chaos?". Gyn. Oneal., 2000, 76, 287.

[35] Silverberg S. G.: "Problems in the differential diagnosis of endometrial hyperplasia and carcinoma". Mod. Pathol., 2000, 13, 309.

[36] Terakawa N., Kigawa J., Taketani Y., Yoshikawa H., Yajima A., Noda K. et al.:'The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group". J. Obstet Gynecol., 1997, 23, 223.

[37] Trope C. G., Marth C., Scheistroen M., Abeler V. M.: "Review endometrial hyperplasia - diagnosis and treatment". Tidsskr Nor. Laegeforen, 1999, 119, 2030.

[38] " FIGO special report on gynecologic cancer". Int. J. Gynec. Obstet. Special Issue (Guest eds.). Benedet J. L., Pecorelli S., 2000, 70 (2), 231.